Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure

Heart

Volumn 91, Issue 7, 2005, Pages 914-919

  Leslie, S J ^a   Spratt, J C S ^a   McKee, S P ^a   Strachan, F E ^a   Newby, D E ^a   Northridge, D B ^a   Denvir, M A ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BISOPROLOL; BUMETANIDE; CARVEDILOL; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIGOXIN; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; FUROSEMIDE; LISINOPRIL; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PRAVASTATIN; SIMVASTATIN; SPIRONOLACTONE; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HEART FAILURE; HEART OUTPUT; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIAC OUTPUT; CARDIAC OUTPUT, LOW; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ENDOTHELIN-1; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PIPERIDINES; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME; VENTRICULAR FUNCTION;

EID: 21044434629     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.040386     Document Type: Article

References (32)

1. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;334:852-4.
2. Haynes WG, Ferro CJ, O'Kane KPJ, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation 1996;93:1860-70.
3. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998;338:784-90.
4. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-93.
5. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998;16:1081-98.
6. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-6.
7. Spratt JCS, Goddard J, Patel N, et al. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and reduced peripheral vascular resistance in healthy men. Br J Pharmacol 2001;134:648-54.
8. Strachan FE, Spratt JC, Wilkinson IB, et al. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999;33:581-5.
9. Hiroe M, Hirata Y, Fujita N, et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991;68:114-5.
10. McMurray JJ, Ray SG, Abdullah I, et al. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-9.
11. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
12. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-6.
13. Krum H, Goldsmith R, Wilshire-Clement M, et al. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995;75:1282-3.
14. Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997;18:254-8.
15. A receptor antagonist, in chronic heart failure. Lancet 1998;352:201-2.
16. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000;101:2922-7.
17. Spieker LE, Mitrovic V, Noll G, et al. Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure. J Am Coll Cardiol 2000;35:1745-52.
18. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
19. Packer M, Caspi A, Charlon V, et al. Multicenter, double-blind, placebo controlled study of long-term endothelin blockade with bosentan in chronic heart failure: results of the REACH-1 trial. Circulation 1998;98(suppl 1):3.
20. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-8.
21. Scholcher C, Cotter G, Reisin L, et al. The dual endothelin antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 2001;142:340-9.
22. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;42:140-7.
23. Cowburn PJ, Cleland JG. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J 2001;22:1772-84.
24. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the heart failure ET(A) receptor blockade trial (HEAT). Circulation 2002;106:2666-72.
25. Coletta A, Thackray S, Nikitin N, et al. Clinical trials update: highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002;4:381-8.
26. Goddard J, Webb DJ. Endothelin antagonists and hypertension: a question of dose? Hypertension 2002;40:e1-2.
27. Newby DE, Goodfield NER, Flapan AD, et al. Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II. Heart 1998;80:134-41.
28. Plumpton C, Ferro G, Haynes WG, et al. The increase in human plasma immunoreactive endothelin but not endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996;119:311-4.
29. McCulloch KM, MacLean MR. Endothelin B receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. J Cardiovasc Pharmacol 1995;3:S169-76.
30. Tsutomoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994;23:1427-33.
31. Rubin U, Badesch DB, Barst RJ, et al. Bosentan therapy far pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
32. Love MP, Ferro CJ, Haynes WG, et al. Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res 2000;47:166-72.